Article

PDF
Access to the PDF text
Service d'aide à la décision clinique
Advertising



Journal Français d'Ophtalmologie
Volume 36, n° 1
pages e1-e4 (janvier 2013)
Doi : 10.1016/j.jfo.2012.04.013
Received : 24 January 2012 ;  accepted : 10 April 2012
Cas cliniques électroniques

Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy
Traitement par ranibizumab de la néovascularisation choroïdienne compliquant la dystrophie vitelliforme de l’adulte
 

Figure 1




Figure 1 : 

Fundus autofluorescence (FAF) of the right eye (A) and left eye (B) showing the vitelliform material as hyperautofluorescent; some hypo-autofluorescent changes are evident in the left macula (B). Spectral-domain optical coherence tomography (SD-OCT) macular scans of both eyes (C and D) show the vitelliform material as a highly reflective dome-shaped lesion located between the photoreceptor layer (inner segments (IS)/outer segments (OS) junction) and retinal pigment epithelium (RPE). On SD-OCT, the left eye IS/OS junction appeared markedly disrupted. Fluorescein angiography (E and F) shows inhomogeneous hyper-fluorescence whitin the macula of both eyes, and a focal hyperfluorescence in the upper perimacular area of the left eye (arrowhead).


Figure 2




Figure 2 : 

Indocyanine green angiography (ICGA) of the left eye (A and B) showing a late focal hyperfluorescence (“hot spot”) (arrowhead) in correspondence of the Type 3 choroidal neovascularization (CNV). Spectral-domain optical coherence tomography (SD-OCT) scan (C) actually referenced on the ICGA (A) hot spot (Type 3 CNV) shows a small localized elevation of the retinal pigment epithelium (RPE) and the “flap sign” (asterisks), as well as the associated intraretinal exudative changes (C). Late ICGA frame showing resolution of the “hot spot” (open arrowhead) one month after the third and last injection of ranibizumab (D and E). SD-OCT (F) scan referenced on the ICGA frame (D) shows, one month after the third and last injection of ranibizumab, still a small elevation of the RPE (arrow), but complete resolution of the associated exudative retinal changes.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline